AtonRa Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AtonRa Partners’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$413K	Sell	5,772 -566	-9%	-$32.6K	0.82%	52
2023 Q3	$330K	Sell	6,338 -1,485	-19%	-$86.5K	0.69%	71
2023 Q2	$495K	Sell	7,823 -724	-8%	-$45.1K	0.77%	59
2023 Q1	$463K	Sell	8,547 -948	-10%	-$45.8K	0.68%	69
2022 Q4	$502K	Sell	9,495 -2,568	-21%	-$129K	0.64%	70
2022 Q3	$561K	Sell	12,063 -158	-1%	-$8.25K	0.55%	83
2022 Q2	$698K	Buy	+12,221	New	+$693K	0.64%	71

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AtonRa Partners's ITCI Position: Q4 2023 in Review

AtonRa Partners reduced its Intra-Cellular Therapies Inc. (ITCI) stake by 8.9% in Q4 2023, selling an estimated $32.6K and leaving 5,772 shares worth $413K. The position accounts for 0.82% of the portfolio, ranked #52.

AtonRa Partners first reported a position in ITCI in Q2 2022 and has held it in 7 quarters since. The position peaked at $698K in Q2 2022. 333 funds tracked by Wall St. Rank hold ITCI as of Q4 2023.

AtonRa Partners held 5,772 shares of Intra-Cellular Therapies Inc. worth $413K as of Q4 2023.
AtonRa Partners sold 566 Intra-Cellular Therapies Inc. shares in Q4 2023, an estimated $32.6K.
Intra-Cellular Therapies Inc. made up 0.82% of AtonRa Partners's portfolio in Q4 2023, its #52 holding.
AtonRa Partners first reported a position in Intra-Cellular Therapies Inc. in Q2 2022 and has held it in 7 quarters since.
AtonRa Partners's Intra-Cellular Therapies Inc. position peaked at $698K in Q2 2022.
333 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.